Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)

@article{Goldfine2013TargetingIU,
  title={Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)},
  author={Allison B Goldfine and J. Stewart Buck and Cyrus V Desouza and Vivian A. Fonseca and Yii-Der I. Chen and Steven E. Shoelson and Kathleen A. Jablonski and Mark A Creager},
  journal={Diabetes Care},
  year={2013},
  volume={36},
  pages={4132 - 4139}
}
OBJECTIVE To test whether inhibiting inflammation with salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted an ancillary study to the National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium… Expand
Response to Comment on Goldfine et al. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care 2013;36:4132–4139
TLDR
Improvement in glycemia but no change in either flow-mediated, endothelium-dependent (FMD) or nitroglycerin-related dilation over 6 months in salsalate compared with placebo-treated patients is demonstrated. Expand
Comment on Goldfine et al. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care 2013;36:4132–4139
TLDR
The authors concluded that their findings suggest that salsalate does not inhibit vascular inflammation, inflammation does not cause endothelial dysfunction in patients with T2D, and the potential benefits of salalate were masked by the unfavorable changes in serum serum cholesterol. Expand
Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?
TLDR
Evidence is collected from randomized controlled trials evaluating the effect of anti-inflammatory drugs on indices of glycemic control and/or cardiovascular events in people with type 2 diabetes to support the concept that targeting inflammation pathways may ameliorate gly glucose control and also reduce cardiovascular complications in type 2abetes. Expand
EFFECT OF HIGH-INTENSITY EXERCISE ON ENDOTHELIAL FUNCTION IN PATIENTS WITH T2DM
TLDR
The high-intensity aerobic training improved the vasodilatation response-dependent endothelium, recorded by ultrasound, in patients with metabolic syndrome and type 2 diabetes. Expand
Improving the Assessment of Flow-Mediated Dilation Through Detection of Peak Time in Healthy Subjects and Subjects With Type 2 Diabetes
TLDR
In healthy subjects and subjects with T2DM, assessment of FMD using MDP results in a more accurate and precise assessment leading to a substantial reduction in sample size. Expand
Role of the IL-1 Pathway in Diabetes and Cardiovascular Disease ( CVD ) : Evidence from Epidemiological Studies
Patients with type 2 diabetes (T2D) exhibit chronic activation of the innate immune system in pancreatic islets, in insulin-sensitive tissues, and at sites of diabetic complications. This resultsExpand
Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention.
TLDR
Primary results from the National Heart, Lung, and Blood Institute– funded Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) trial are presented, showing equipoise is clearly present with regard to potential vascular benefits of salalate. Expand
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
TLDR
The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Expand
The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
TLDR
Proof-of-concept clinical studies have validated IL-1β as a target to improve insulin production and action in patients with T2D and large ongoing clinical trials will address the potential ofIL-1 antagonism to prevent cardiovascular and other related complications. Expand
Endothelial Dysfunction in Type 2 Diabetes: Targeting Inflammation
TLDR
The aim of this review is to address the role of inflammation and its mechanisms in endothelial dysfunction associated with diabetes, describing the impact of these conditions on vascular function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes
TLDR
The number of patients studied and the trial duration were insufficient to warrant recommending the use of salsalate for type 2 diabetes at this time, but the drug was otherwise well tolerated. Expand
Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes
TLDR
The results show that salsalate is effective in improving glycemic control in newly diagnosed naïve patients with T2DM and the optimal duration of treatment and sustainability of its effect requires further study. Expand
Salicylate (Salsalate) in Patients With Type 2 Diabetes
TLDR
Salsalate improves glycemia in patients with T2DM and decreases inflammatory mediators and lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of salsalates. Expand
A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance
TLDR
Salsalate therapy was well tolerated, lowered fasting glucose, increased adiponectin and reduced adipose tissue NF-κB activity, and was not correlated with metabolic improvements, suggesting additional mechanisms for metabolic improvement. Expand
Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus.
TLDR
Oral antioxidant therapy improves EDV in T1 but not T2 diabetes, consistent with the lack of clinical benefit in studies that have included primarily T2 diabetic patients. Expand
Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans
TLDR
Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress. Expand
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
TLDR
Angiotensin II type-1 receptor blockers significantly improved the percent flow-mediated dilator response to hyperemia and reduced plasma levels of malondialdehyde in patients with mild to moderate hypertension. Expand
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
TLDR
Infliximab treatment was associated with a significant increase of both total cholesterol and HDL-cholesterol levels, which correlated with decreasing disease activity, however, this was not accompanied by a favorable effect on the atherogenic index. Expand
Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes
TLDR
This work studied the efficacy of salsalate in reducing glycemia and insulin resistance and potential mechanisms of action to validate NF‐κB as a potential pharmacologic target in diabetes. Expand
Clinical Correlates and Heritability of Flow-Mediated Dilation in the Community: The Framingham Heart Study
TLDR
Increasing age, systolic blood pressure, BMI, and smoking were associated with lower FMD% in the authors' community-based sample, whereas prior exercise and increasing heart rate were associatedWith higher FMD%. Expand
...
1
2
3
4
5
...